Replimune Group Inc (REPL)
Healthcare
Biotechnology
11.90 $
+6.3%
vs. previous close
Closing price · As of: 3. Aug 2026
Replimune Group Inc (REPL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -56 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -49 | -44 | -47 | -46 | -49 | -39 | -51 | -54 | -77 | -81 | -66 | -56 | -280 | |
| 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.9 | 1.0 | 0.8 | 0.9 | 0.8 | 1.4 | 0.4 | 3.5 | |
| 8.8 | 9.1 | 8.2 | 7.9 | 9.5 | 8.7 | 8.6 | 8.3 | 8.8 | 8.3 | 7.0 | 8.1 | 32 | |
| 9.1 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -3.3 | 7.4 | -0.8 | 2.2 | -3.6 | 8.9 | 3.3 | 13 | -0.4 | -6.9 | -3.4 | 6.9 | -3.8 | |
| 0.4 | 1.8 | 1.7 | 1.7 | 1.7 | 2.1 | 1.8 | 1.1 | 2.7 | 1.3 | 0.1 | 0.0 | 4.2 | |
| 7.4 | 13 | 54 | 23 | 30 | 0.5 | -46 | -7.7 | 65 | 84 | 75 | 87 | 311 | |
| 1.2 | – | 0.0 | 0.0 | 49 | – | 97 | – | – | – | – | – | – | |
| -0.1 | – | – | – | – | -0.1 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | 35 | 34 | |
| 1.1 | 0.4 | 15 | -0.1 | 97 | 0.0 | 156 | -0.1 | -0.2 | 0.3 | 10 | 56 | 66 | |
| -40 | -30 | 22 | -23 | 77 | -38 | 59 | -61 | -14 | 4.9 | 21 | 86 | 98 | |
| -49 | -45 | -49 | -48 | -51 | -41 | -53 | -55 | -80 | -83 | -66 | -56 | -285 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.